It has been proven that Nicotinamide mononucleotide (NMN) to reverse signs of aging in mice, including decline in glucose intolerance, metabolism and eyesight is set to be tested in 10 human volunteers in Japan for the coming month.
Researchers from the University of New South Wales (UNSW) in 2013, claimed to have formulated a drug using a compound called Nicotinamide mononucleotide (NMN) could help slow down the aging process and has been found to reverse signs of aging and extend the life expectancy in mice.
However, to date, such methods haven’t been tested in humans, but that’s all about to change.
The trial will be conducted in the coming month by Keio University in Japan with ten healthy volunteers to see if the results will be as good and as safe.
Some will ask how does it work? Its NMN stimulates production of sirtuins, a protein class that grow weaker as we age. This drug reverses, not just in the outside signs of aging, but internal symptoms as well, including decline in eyesight, metabolism and glucose intolerance.
“We’ve confirmed a remarkable effect in the experiment using mice, but it’s not clear yet how much [the compound] will affect humans,” lead researcher Shin-ichiro Imai said.
“We’ll carefully conduct the study, which I hope will result in important findings originating in Japan.” Shin-ichiro Imai added.
As the tests will run, there are no proven ways to delay the human aging process but NMN could be the first anti-aging drug to be allowed in the market, if proven effective and safe for humans. Still, it adds new information about the drug and in the process of aging.